title: Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings.
abstract: Studies on safety, immunogenicity and efficacy of the killed, bivalent whole cell oral cholera vaccine (Shanchol) have been conducted in historically endemic settings of Asia. Recent cholera vaccination campaigns in Haiti and Guinea have also demonstrated favourable immunogenicity and effectiveness in nonendemic outbreak settings. We performed a secondary analysis, comparing immune responses of Shanchol from two randomised controlled trials performed in an endemic and a less endemic area (Addis Ababa) during a nonoutbreak setting. While Shanchol may offer some degree of immediate protection in primed populations living in cholera endemic areas, as well as being highly immunogenic in less endemic settings, understanding the characteristics of immune responses in each of these areas is vital in determining ideal dosing strategies that offer the greatest public health impact to populations from areas with varying degrees of cholera endemicity.
authors.affiliation: International Vaccine Institute, Seoul, Korea.
authors.forename: Sachin N
authors.initials: SN
authors.lastname: Desai
authors.affiliation: Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
authors.forename: Zenebe
authors.initials: Z
authors.lastname: Akalu
authors.affiliation: Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
authors.forename: Mekonnen
authors.initials: M
authors.lastname: Teferi
authors.affiliation: National Institute of Cholera and Enteric Diseases, Kolkata, India.
authors.forename: Byomkesh
authors.initials: B
authors.lastname: Manna
authors.affiliation: International Vaccine Institute, Seoul, Korea.
authors.forename: Samuel
authors.initials: S
authors.lastname: Teshome
authors.affiliation: International Vaccine Institute, Seoul, Korea.
authors.forename: Ju Yeon
authors.initials: JY
authors.lastname: Park
authors.affiliation: International Vaccine Institute, Seoul, Korea.
authors.forename: Jae Seung
authors.initials: JS
authors.lastname: Yang
authors.affiliation: International Vaccine Institute, Seoul, Korea.
authors.forename: Deok Ryun
authors.initials: DR
authors.lastname: Kim
authors.affiliation: National Institute of Cholera and Enteric Diseases, Kolkata, India.
authors.forename: Suman
authors.initials: S
authors.lastname: Kanungo
authors.affiliation: International Vaccine Institute, Seoul, Korea.
authors.forename: Laura
authors.initials: L
authors.lastname: Digilio
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002771:Cholera / Q000453:epidemiology / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000276:immunology*; D002985:Clinical Protocols; D019353:Endemic Diseases; D005002:Ethiopia / Q000453:epidemiology; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D011634:Public Health; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology; D055815:Young Adult
chemical_list: D022121:Cholera Vaccines; D015164:Vaccines, Inactivated
keywords: cholera; choléra; cólera; immunogenicity; immunogénicité; inmunogenicidad; oral cholera vaccine; vaccin oral contre le choléra; vacuna oral para el cólera